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Abstract
Background: Elevated plasma levels of asymmetric dimethylarginine (ADMA) has been reported to be associated with
insulin resistance and micro/macrovascular diabetic complications, and may predict cardiovascular events in type 2
diabetic patients. Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is the major enzyme eliminating ADMA in
humans, but the effect of genetic variations in DDAH1 on type 2 diabetes and its long-term outcome are unknown.
Methods: From July 2006 to June 2009, we assessed the association between polymorphisms in DDAH1 and type 2
diabetes in 814 consecutive unrelated subjects, including 309 type 2 diabetic patients and 505 non-diabetic individuals.
Six single nucleotide polymorphisms (SNPs) in DDAH1, rs233112, rs1498373, rs1498374, rs587843, rs1403956, and
rs1241321 were analyzed. Plasma ADMA levels were determined by high performance liquid chromatography. Insulin
sensitivity was assessed by the homeostasis model assessment of insulin resistance (HOMA-IR).
Results: Among the 6 SNPs, only rs1241321 was significantly associated with a decreased risk of type 2 diabetes (AA vs
GG+AG, OR = 0.64, 95% CI 0.47-0.86, p = 0.004). The association remained unchanged after adjustment for plasma
ADMA level. The fasting plasma glucose and log HOMA-IR tended to be lower in subjects carrying the homozygous AA
genotype of rs1241321 compared with the GG+AG genotypes. Over a median follow-up period of 28.2 months, there
were 44 all-cause mortality and 50 major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal
myocardial infarction and stroke). Compared with the GG and AG genotypes, the AA genotype of rs1241321 was
associated with reduced risk of MACE (HR = 0.31, 95% CI: 0.11-0.90, p = 0.03) and all-cause mortality (HR = 0.18, 95% CI:
0.04-0.80, p = 0.02) only in subgroup with type 2 diabetes. One common haplotype (GGCAGC) was found to be
significantly associated with a decreased risk of type 2 diabetes (OR = 0.67, 95% CI = 0.46-0.98, p = 0.04).
Conclusions: Our results provide the first evidence that SNP rs1241321 in DDAH1 is associated with type 2
diabetes and its long-term outcome.
Introduction
Endothelial dysfunction is present from the onset of type 2
diabetes and strongly related to its outcomes [1], and itself
may lead to the development of insulin resistance and dia-
betes [2,3]. Derangement of the L-arginine-nitric oxide
(NO) pathway by asymmetric dimethylarginine (ADMA)
has been implicated as an important contributing factor
for endothelial dysfunction. ADMA is characterized as a
circulating endogenous inhibitor of NO synthase by com-
peting with L-arginine as the substrate [4,5]. Moreover,
ADMA may increase oxidative stress by uncoupling the
electron transport between NO synthase and L-arginine,
which can lead to decrease in the production and availabil-
ity of endothelium-derived NO [6,7]. Elevated plasma
ADMA levels have been observed in patients with various
risk factors for atherosclerosis, including insulin resistance
and type 1/2 diabetes [8-10], and have been reported to be
associated with micro/macrovascular diabetic complica-
tions [11,12]. Moreover, several prospective studies have
demonstrated that elevated plasma ADMA level may pre-
dict adverse cardiovascular events in type 2 diabetic
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any medium, provided the original work is properly cited.patients [13,14]. Taken together, these evidences suggest
that ADMA may be a novel pathogenic factor of diabetes.
In the human body, 80% of ADMA is metabolized to
citrulline by dimethylarginine dimethylaminohydrolase
(DDAH) and the remainder is excreted by the kidneys
[15]. There are 2 isoforms of DDAH, with DDAH1 pre-
sent mainly in the kidneys and brain, while DDAH2 is
predominantly found in the heart and kidney [16]. Mice
over-expressing DDAH1 have lower plasma ADMA
levels and are insulin-sensitive, presumably by reducing
g l u c o s eu p t a k eb ys k e l e t a lm u s c l eo rb yd i m i n i s h i n g
insulin signaling in the liver [17]. However, the effect of
genetic variations of DDAH1 on type 2 diabetes has not
been reported. In this prospective study, we assessed the
association between single nucleotide polymorphisms
(SNPs) in DDAH1 and type 2 diabetes and their long-
term outcome in a population undergoing diagnostic
coronary angiography.
Materials and methods
Study population
From July 2006 to June 2009, 814 consecutive unrelated
subjects, including 309 type 2 diabetic patients and 505
non-diabetic control subjects, were recruited at Taipei
Veterans General Hospital from the patients scheduled to
undergo coronary angiography for chest pain and/or sus-
pected coronary artery disease. Exclusion criteria included
patients with severe liver disease and end-stage renal dis-
ease, active infectious disease, chronic or acute inflamma-
tory disease, malignancy, and unstable hemodynamic
status. Thorough medical histories of all participants were
recorded. Type 2 diabetes mellitus was diagnosed accord-
ing to the diagnostic criteria defined by the American Dia-
betes Association in 2003 [18] or when the individual was
receiving oral hypoglycemic agents or insulin injection
therapy at the time of recruitment. Most of the diabetic
patients have medication with oral hypoglycemic agents
(n = 244, 79.0%, including metformin, n = 185, 60.0%, sul-
fonylurea, n = 94, 30.4%, thiazolidinedione, n = 10, 3.2%,
acarbose, n = 30, 9.7%), or insulin alone (n = 49, 15.8%),
or insulin combined with oral hypoglycemic agents (n = 8,
2.6%), while a few received only dietary therapy only (n =
8, 2.6%). Hypertension was diagnosed according to
the Seventh Joint National Committee criteria [19] or if
the patient was receiving anti-hypertensive drugs. All med-
ications, cigarette smoking and beverages containing alco-
hol or caffeine were withdrawn for at least 12 hours.
Fasting blood samples were collected in EDTA tubes for
the measurement of ADMA, blood sugar, insulin, and for
other biochemical and genotype analyses before the coron-
ary angiography in the morning. After coronary angiogra-
phy, all patients with ≥50% stenosis in at least one major
coronary artery underwent successful revascularization
procedures, including percutaneous coronary intervention
or coronary artery bypass surgery if indicated. All patients
were prospectively followed by monthly office visit or by
telephone contact and chart review for the occurrence of
all-cause mortality and first-ever major adverse cardiovas-
cular events (MACE), defined as cardiovascular death,
stroke and non-fatal myocardial infarction. Cardiovascular
death was diagnosed as any death with definite cardiovas-
cular cause or any death that was not clearly attributed to
a non-cardiovascular cause. Myocardial infarction was
defined as the presence of significant new Q waves in at
least 2 electrocardiographic leads or of symptoms compa-
tible with myocardial infarction associated with increase in
creatine kinase-MB fraction ≥3 times the upper limit of
the reference range. The study protocol was approved by
the Institutional Review Board at Taipei-Veterans General
Hospital and all participants provided written informed
consent.
Laboratory measurements
Blood samples were centrifuged at 3000 rpm for 10 min-
utes immediately after collection and plasma was frozen
until analysis. Plasma L-arginine and ADMA concentra-
tions were determined by high performance liquid chro-
matography as described previously [20]. The recovery
rate for ADMA was > 90%, and the within-assay and
between-assay variation coefficients were not more than
7% and 8%, respectively. Fasting serum creatinine, total
and high-density lipoprotein (HDL)-cholesterol, triglycer-
ides, and blood sugar levels were determined by using an
auto-analyzer (Model 7600-310, Hitachi, Tokyo). Low-
density lipoprotein (LDL)-cholesterol levels were calcu-
lated according to the Friedewald formula. Fasting
plasma insulin concentrations in non-diabetes subjects
were measured by enzyme immunoassay (Mercodia Insu-
lin ELISA, Mercodia AB, Uppsala, Sweden). Insulin sensi-
tivity was assessed by the homeostasis model assessment
of insulin resistance (HOMA-IR) and b-cell function
(HOMA-b), calculated basing on Matthews et al. [21]. As
most patients with type 2 diabetes were treated with oral
hypoglycemic agents or insulin, these phenotypes were
evaluated in non-diabetic controls and diabetic subjects
with only diet control to avoid the influence of treatment
(n = 513). The body mass index (BMI) was obtained
from the ratio of weight (kg) to height squared (m
2). The
estimated glomerular filtration rate (eGFR) was calcu-
lated according to the simplified version of the Modifica-
tion of Diet in Renal Disease Study prediction equation
formula, modified by Ma et al. for Chinese patients
(eGFR = 175×plasma creatinine
-1.234 ×a g e
-0.179 ×0 . 7 9[ i f
female]) [22].
Genotyping
Genomic DNA was extracted from leukocytes by stan-
dard procedures using Gentra Purgene Blood Kit
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rs233112, rs1498373, rs1498374, rs587843, rs1403956,
rs1241321 were selected from the HapMap with minor
allele frequencies >0.2 and an r
2 threshold of 0.8 in the
Han population. SNP rs233112 was genotyped by
restriction fragment length polymorphism and the
others by high-throughput matrix-assisted laser deso-
rption/ionization time-of-flight (MALDI-TOF) mass
spectrometry using the SEQUENOM Mass ARRAY sys-
tem (Sequenom, Sam Diego, CA, USA). The success
rate for MALDI-TOF mass spectrometry is 99.7%. All
genotypes were determined blinded to the clinical char-
acteristics and 1 negative control and 3 sequenced posi-
tive controls were tested on each plate to ensure
consistency in genotyping. Primer sequences are avail-
able upon request.
Statistical analysis
Continuous data are presented as the mean ± standard
deviation or with a confidence interval (CI) of 95% and
differences between groups were compared with one-
way analysis of variance (ANOVA) or two-sample
t-tests. Categorical data were compared by Chi-square
test or Fisher’s exact test. Univariate logistic/linear
regression analysis for the association with type 2 dia-
betes/log HOMA-IR were tested first for age, gender,
hypertension, hypercholesterolemia, smoking, BMI,
ADMA, L-arginine/ADMA ratio, eGFR, and genotypes/
haplotypes. Those factors with p < 0.1 were included
into the multivariate logistic/linear regression analysis.
Estimates of pairwise linkage disequilibrium (LD) values
(D’) were obtained using the HaploView software (ver-
sion 4.2). Haplotype blocks were estimated using the CI
method by Gabriel et al. [23]. Haplotype frequencies
were estimated by the GENECOUNTING program (ver-
sion 1.9). Haplotypes with frequencies greater than 5%
were considered in the analysis and the most common
haplotype was used as the reference.
Actuarial event-free survival curves were estimated
using the Kaplan-Meier method and compared by log-
rank test. The univariate Cox regression analysis was
performed first to determine the association with the
risk of all-cause death and MACE in all subjects, and
the variables tested included age, gender, diabetes,
hypertension, hypercholesterolemia, smoking, BMI,
ADMA, eGFR, and genotypes/haplotypes. Those with a
p value < 0.1 were included into the multivariate Cox
regression analysis. The plasma ADMA level was tested
as a continuous or categorical variable. The hazards
ratio (HR) and 95% CI were calculated. A p value of less
than 0.05 was considered statistically significant. The
SPSS 17.0 (SPSS Inc., Chicago, Illinois) software package
was used for statistical analysis.
Results
Clinical characteristics of cases and controls are sum-
marized in Table 1. In comparison with controls, those
with type 2 diabetes had significantly higher BMI, trigly-
ceride, and lower HDL-cholesterol, which are character-
istics of type 2 diabetes. In particular, patients with type
2 diabetes had lower eGFR and were more likely to have
hypertension. Lower LDL- cholesterol and total choles-
terol levels in diabetic patients may be due to their
more common use of statins (p = 0.06). The prevalence
of hypercholesterolemia was nearly identical in both
groups (Table 1).
Plasma ADMA levels, L-arginine/ADMA ratio and type 2
diabetes
Plasma ADMA levels in all study participants were corre-
lated positively with age (r = 0.20, p < 0.001) and nega-
tively with eGFR (r = -0.21, p < 0.001), but were similar
between individuals with and without type 2 diabetes
(Table 1). Plasma L-arginine level and the L-arginine/
ADMA ratio, an index of L-arginine bioavailability, were
both significantly lower in patients with type 2 diabetes
(Table 1). By multivariate logistic/linear regression analy-
sis, the L-arginine/ADMA ratio was associated with type
2 diabetes (OR = 0.95/L-arginine/ADMA ratio increase
of 10, 95% CI = 0.93-0.97, p < 0.001) and was negatively
associated with the log HOMA-IR in non-diabetic sub-
jects (r = -0.157, p < 0.0001), but plasma ADMA was
not.
DDAH1 genotype and type 2 diabetes
Genotype distributions for the 6 DDAH1 SNPs are sum-
marized in Table 2 and all are in Hardy-Weinberg equili-
brium (p > 0.01). SNPs rs1241321-rs1403956 and
rs233112-rs1498374-rs1498373 were in tight LD accord-
ing to D’ and belong to 2 haplotype blocks as revealed in
the HapMap (Figure 1). We first assessed the association
of each DDAH1 SNP with type 2 diabetes (Table 2).
Among the 6 SNPs, only rs1241321 was significantly
associated with the risk of type 2 diabetes in the multi-
v a r i a t el o g i s t i cr e g r e s s i o na n a l y s i s( Aversus G: OR =
0.75, 95% CI = 0.60-0.93, p = 0.008 and p = 0.048 when
adjusted for multiple comparisons; AA versus GG + AG,
OR = 0.64, 95% CI = 0.47-0.87, p = 0.004 and p = 0.024
when adjusted for multiple comparisons). The associa-
tion remained unchanged after adjustment for plasma
ADMA levels (OR = 0.64, 95% CI = 0.47-0.86, p = 0.004).
Moreover, the fasting plasma glucose and log HOMA-IR
in non-diabetic subjects tended to be lower in subjects
carrying homozygous AA genotype (Table 3). The base-
line clinical characteristics of subjects with AA and GG +
AG genotypes are summarized in Table 4 and there were
no significant difference between groups except that the
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2 diabetes.
Next we examined the association between DDAH1
polymorphisms and plasma ADMA levels by multivari-
ate linear analysis and found that 4 of the 6 SNPs,
except rs1241321 and rs587843, were associated with
plasma ADMA levels, with the most significant being
the SNP rs1498373 (p = 1.4 × 10
-5). However, there
were no associations between these SNPs and plasma
L-arginine levels or L-arginine/ADMA ratio (Table 5).
Clinical outcomes and ADMA/DDAH 1 genotypes
Over a median follow-up period of 28.2 months (25-75%
interval: 21.2-46.1 months), there were 44 all-cause
deaths (including 24 deaths in type 2 diabetic patients)
and 50 MACE (including 31 cardiovascular death, 2
stroke and 17 non-fatal myocardial infarction; including
22 MACE in type 2 diabetic patients). The plasma
ADMA level in patients with all-cause mortality and
MACE was significantly higher than that in individuals
without adverse events (all-cause mortality: 0.53 ±
0.14 μmol/l versus 0.45 ± 0.10 μmol/l, p < 0.001;
MACE: 0.53 ± 0.13 μmol/l versus 0.45 ± 0.10 μmol/l,
p < 0.001). In multivariate Cox regression analysis, the
ADMA quartile was identified as an independent predic-
tor of future all-cause mortality (HR = 1.58/ADMA
quartile increase, 95% CI = 1.15-2.16; p = 0.004) and
MACE (HR = 1.39/ADMA quartile increase, 95% CI =
1.03-1.86; p = 0.03). By considering the plasma ADMA
level as a continuous variable, the plasma ADMA level
remained a significant independent predictor for all-
cause mortality (HR = 1.59/ADMA increase of 0.1
μmol/l, 95% CI = 1.28-1.97; p < 0.001) and MACE (HR
= 1.47/ADMA increase of 0.1 μmol/l, 95% CI = 1.18-
1.84; p = 0.001). In the multivariate analyses in sub-
groups of diabetic and non-diabetic subjects, the ADMA
quartile remained a significant predictor of all-cause
mortality and MACE only in non-diabetic subgroup
(non-diabetic group: all-cause mortality: HR = 1.66/
ADMA quartile increase, 95% CI = 1.07-2.56; p = 0.02;
MACE: HR = 1.94/ADMA quartile increase, 95% CI =
1.22-3.08; p = 0.005; diabetic subgroup: both p = NS;
interaction p = 0.04 for all-cause mortality, p = 0.02 for
MACE, respectively).
Table 1 Clinical characteristics of type 2 diabetic patients and non-diabetic subjects
Type 2 DM patients n = 309 Non-DM subjects n = 505 P value
Age (years) 65.4 ± 10.4 64.8 ± 10.8 0.57
Gender (Women/men) 74/235 123/382 0.90
BMI (Kg/m
2) 27.2 ± 3.9 25.6 ± 3.4 < 0.001
Hypertension (%) 252 (81.0) 348 (68.9) < 0.001
Smoking (%) 64 (20.7) 106 (21.0) 0.93
Hypercholesterolemia (%) 139 (45.1) 228 (45.1) 1.00
Cholesterol (mg/dl)
Total 164.7 ± 33.4 175.1 ± 37.3 < 0.001
HDL-Cholesterol 40.1 ± 11.1 44.9 ± 12.7 < 0.001
LDL-Cholesterol 99.6 ± 28.4 110.0 ± 33.6 < 0.001
Triglyceride (mg/dl) 155.0 ± 96.8 138.0 ± 85.4 < 0.001
Creatinine (mg/dl) 1.3 ± 1.0 1.1 ± 0.5 < 0.001
eGFR (ml/min per 1.73 m
2) 70.8 ± 30.0 80.1 ± 24.9 < 0.001
Fasting blood sugar(mg/dl) 138.0 ± 48.3 92.7 ± 14.5 < 0.001
ADMA (μmol/l) 0.46 ± 0.09 0.45 ± 0.10 0.12
L-arginine (μmol/l) 88.3 ± 29.7 97.3 ± 33.3 < 0.001
L-arginine/ADMA 196.0 ± 67.0 225.0 ± 86.1 < 0.001
Medications
Anti-platelet drug 272 (88.0) 420 (83.2) 0.07
Statins 144 (46.4) 201 (39.8) 0.06
ACE-Inhibitor/ARB 108 (35.0) 111 (22.0) <0.001
Calcium channel blocker 69 (22.3) 115(22.8) 0.88
Hypoglycemic treatments
Insulin (%) 49 (15.8) - -
OHA (%) 244 (79.0) - -
Insulin + OHA (%) 8 (2.6) - -
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. BMI: body mass index; eGFR: estimated glomerular filtration rate; OHA: oral
hypoglycemic agents.
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and long-term outcome, Figure 2 showed the Kaplan-
Meier estimates of all-cause mortality and probability of
MACE-free survival of patients stratified by genotype of
DDAH1 rs1241321 in diabetic and non-diabetic groups,
and the prognosis of diabetic patients carrying the
rs1241321 AA genotype appeared to be better than those
carrying GG +AG genotype. Multivariate Cox regression
analysis showed that while AA genotype in the DDAH1
rs1241321 was not a predictor for long-term outcome in
the whole population, it was independently associated
with reduced risk for long-term all-cause mortality (AA
versus GG + AG: HR = 0.18, 95% CI = 0.04-0.80, p =
0.02) and MACE (AA versus GG + AG: HR = 0.31, 95%
CI = 0.11-0.90, p = 0.03) in type 2 diabetic patients but
not in the non-diabetic subgroup (interaction p = 0.16
for all-cause mortality, p = 0.05 for MACE, respectively).
There were no significant association between the other
SNPs and the long-term clinical outcomes.
Haplotype-based analysis
Seven common haplotypes with >5% frequency were
reconstructed in the study population and accounted for
93.1% of all the estimated haplotypes (Table 6). There
was a significant difference in the distribution of haplo-
type frequencies between subjects with and without type
2 diabetes (permutation test by GENECOUNTING pro-
gram, p = 0.03). In a multivariate logistic regression ana-
lysis adjusted for age, gender, BMI and hypertension, the
haplotype H5 (GGCAGC) was found to be significantly
associated with a decreased risk of type 2 diabetes
(OR = 0.67, 95% CI = 0.46-0.98, p = 0.04, Table 6),
which remained unchanged after adjustment for plasma
ADMA levels (OR = 0.67, 95% CI = 0.46-0.98, p = 0.04,
Table 6). On the other hand, after adjusting for age,
gender and eGFR, a significant association with higher
plasma ADMA levels was found in haplotypes H3
(GATAAG, p = 4.1 × 10
-4) and H4 (GGTGGC, p =
2.8 × 10
-4). There was no significant association between
diabetes-related phenotypes and other genotypes or hap-
lotypes. Moreover, no common haplotype was associated
with long-term outcomes.
Discussion
In this study, SNP rs1241321 in DDAH1 was found to
be associated with a higher risk of type 2 diabetes inde-
pendently of the plasma ADMA level. In addition, indi-
viduals with an AA genotype at rs1241321 appeared to
Table 2 Association between the DDAH1 gene polymorphisms and type 2 diabetes
SNP ID Genotype Type 2 DM patients, n (%) Non-DM subjects, n (%) Multivariate adjusted OR* (95% CI), p value
rs233112
AA 98 (31.8) 149 (29.6)
AG 153 (49.7) 256 (50.9) 0.99 (0.78-1.19)
GG 57 (18.5) 98 (19.5) 0.72
rs1498374
GG 217 (70.2) 347 (69.0)
AG 85 (27.5) 146 (29.0) 0.99 (0.74-1.32)
AA 7 (2.3) 10 (2.0) 0.94
rs1498373
CC 138 (44.8) 237 (46.9)
CT 137 (44.5) 231 (45.7) 1.21 (0.96-1.52)
TT 33 (10.7) 37 (7.3) 0.11
rs1241321
GG 49 (15.9) 66 (13.1)
AG 160 (51.8) 225 (44.6) 0.75 (0.60-0.93)
AA 100 (32.4) 214 (42.4) 0.008**
rs1403956
GG 180 (58.3) 295 (58.5)
AG 118 (38.2) 185 (36.7) 0.99 (0.77-1.27)
AA 11 (3.6) 24 (4.8) 0.92
rs587843
CC 46 (14.9) 87 (17.3)
CG 169 (54.7) 239 (47.5) 0.93 (0.75-1.15)
GG 94 (30.4) 177 (35.2) 0.51
*Odds ratio (OR) for rs233112: A versus G; rs1498374: A versus G; rs1498373: T versus C; rs1241321 A versus G; rs1403956 A versus G; rs587843: G versus C.
**adjusted for multiple comparison: p = 0.048; AA vs GG +AG: OR (95% CI) = 0.64 (0.47-0.87), p = 0.004.
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individuals. Over a median follow-up period of
28.2 months, AA genotype at rs1241321 was associated
with better long-term clinical outcome in diabetic sub-
group. In contrast, some SNPs of DDAH1, especially the
rs1498373, might influence the plasma level of ADMA.
However, with the exception of rs1241321, none of
these SNPs or the plasma ADMA level was associated
with type 2 diabetes, suggesting that the interaction of
DDAH1 variants with type 2 diabetes may not be
directly related to its enzymatic activity, i.e. not just sim-
ply mediated by the plasma ADMA level. We also iden-
tified a common haplotype H5 (GGCAGC) that was
associated with reduced risk of type 2 diabetes.
It is well recognized that type 2 diabetes and its meta-
bolic derangements such as hyperinsulinemia, hypergly-
cemia, dyslipidemia, and increased oxidative stress are
associated with NO-mediated endothelial dysfunction
[1]. In contrast, endothelial dysfunction may lead to
attenuated glucose uptake in insulin-sensitive tissues,
hyperglycemia, and ultimately to the development of
insulin resistance and type 2 diabetes [2,3]. Furthermore,
impaired NO bioavailability plays a pivotal role in the
regulation of glucose-stressed endothelial progenitor cell
dysfunction in type 2 diabetes, and anti-oxidant treat-
ment with superoxide dismutase may restore their func-
tion [24]. ADMA, an endogenous competitive inhibitor
of NO synthase, is known to impair NO bioavailability
Figure 1 Linkage disequilibrium plot for 6 SNPs in the DDAH1 gene. The Haplotype blocks were estimated according to the CI method
using the criteria of Gabriel et al (Science 2002, 296:2225-2229 [23]).
Table 3 Association between diabetic phenotypes and DDAH1 SNP rs 1241321 in non-diabetic subjects
AA (n = 212) GG + AG (n = 301) P value*
Fasting plasma glucose 91.2 (89.6-92.8) 93.7 (91.8-95.6) 0.048
HOMA-IR 3.0 (2.7-3.3) 3.2 (2.9-3.5) 0.15
HOMA-b 47.6 (42.6-52.6) 51.2 (46.8-55.6) 0.18
Log HOMA-IR 0.36 (0.31-0.40) 0.41 (0.38-0.45) 0.015
HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-b: homeostasis model assessment of b-cell function. *: adjusted for age, sex and BMI.
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might inhibit the mobilization, differentiation and func-
tion of endothelial progenitor cell [25]. Therefore, accu-
mulating evidences suggested that ADMA might be
implicated in the pathogenesis of insulin resistance
[8,26] and the vasculopathy in type 2 diabetes. As
human plasma ADMA is eliminated primarily by the
DDAH enzymes [15], it has been demonstrated that
both heterozygous DDAH1 knock-out mice and vascular
endothelial-specific DDAH1-deficient mice showed sig-
nificantly increased ADMA levels and endothelial dys-
function [27,28]. In addition, over-expression of DDAH1
led to reduced plasma ADMA level and enhanced insu-
lin sensitivity [17,29]. Wolf et al. recently reported that
reduced urinary ADMA concentrations were associated
with impaired cardiac function and might predict future
cardiovascular risk. Moreover, they found that the urin-
ary dimethylamine (the metabolic breakdown product of
ADMA by DDAH)/ADMA ratio was significantly
increased in patients with severe coronary artery disease
(CAD), suggesting that DDAH might be up-regulated in
CAD [30]. However, the influence of DDAH1 poly-
morphisms on plasma ADMA levels in human is rarely
addressed. Recently, Abhary et al. reported that the
genetic variation in DDAH1 was significantly associated
with serum ADMA levels in subjects with type 2 diabetes
[31]. They tested 26 tag SNPs in DDAH1,i n c l u d i n g
rs1241321, rs587843, and rs1498373 that we tested in the
present study. Similar to our results, they showed that,
among the 26 tag SNPs, rs1498373 was significantly asso-
ciated with serum ADMA level, while rs1241321 and
rs587843 were not. Nevertheless, since all these SNPs are
located in the intron regions of DDAH1,t h e i rf u n c t i o n a l
significances and the underlying mechanisms by which
these polymorphisms affect the serum ADMA levels
remain unclear. In contrast, in the present study it was
intriguing to find that SNP rs1241321, which did not
affect the plasma ADMA level, was associated with insu-
lin sensitivity, the risk of type 2 diabetes and their long-
term outcome. Furthermore, adjustment for the plasma
ADMA level did not attenuate its effect on the risk of
type 2 diabetes or its prognostic value, suggesting that its
role on type 2 diabetes is not likely to be mediated
through plasma ADMA. To the best of our knowledge,
the present study is the first one to investigate the asso-
ciation of DDAH1 polymorphism with type 2 diabetes
and to assess the prognostic significance of DDAH1 poly-
morphism in these patients. However, the functional
significance of SNP rs1241321 remains unclear. SNP
rs1241321 is located in intron 1 of DDAH1 (Chr1:
85,927,629, GRCh37), about 3 Kb from the novel
DDAH1 c.-397_ -396insGCGT polymorphism (Chr1:
85,931,124, GRCh37), which was recently reported to dis-
rupt the binding of transcription factors and resulted in
significantly reduced DDAH1 transcription and elevated
plasma ADMA level [32]. Nevertheless, the correlation
between these two polymorphisms may not be high,
because of the relatively large discrepancy in their minor
allele frequencies (0.377 for rs1241321, and 0.10 for
c.-397_ -396insGCGT in Chinese Han Denver). Caplin et
al. reported that the DDAH1 SNP rs233112 that we
tested was significantly associated with plasma ADMA
level in several cohorts of chronic kidney disease [33].
Intriguingly, they found that another DDAH1 SNP
rs17384213 GG genotype was associated with lower
plasma ADMA level, increased expression of DDAH1
mRNA in kidney allograft, but in contrast was associated
with more rapid decline of renal function. The latter
observation was conflicting with a previous observational
study [34]. Similarly, the functional significances of these
DDAH1 SNPs were also unknown. Although possible
mechanisms include effects on local tissue or the intra-
cellular concentration of ADMA, the exact functional
Table 4 Clinical characteristics of subjects with rs1241321
AA genotype and GG + AG genotypes
AA
n = 314
GG + AG
n = 500
P value
Age (years) 64.3 ± 10.2 65.5 ± 10.2 0.13
Gender (Women/men) 77/237 120/380 0.87
BMI (Kg/m
2) 26.2 ± 3.8 26.2 ± 3.5 0.98
Diabetes (%) 100 (31.4) 209 (41.8) 0.004
Hypertension (%) 233 (74.2) 367 (73.4) 0.80
Smoking (%) 67 (21.3) 103 (20.6) 0.80
Hypercholesterolemia (%) 155 (49.4) 212 (42.4) 0.05
Cholesterol (mg/dl)
Total 171.2 ± 35.2 171.2 ± 36.9 0.99
HDL-Cholesterol 43.7 ± 12.3 43.1 ± 12.2 0.49
LDL-Cholesterol 105.5 ± 31.1 106.1 ± 32.7 0.80
Triglyceride (mg/dl) 146.4 ± 88.3 149.8 ± 92.4 0.61
Creatinine (mg/dl) 1.2 ± 0.7 1.2 ± 0.9 0.79
eGFR (ml/min per 1.73 m
2) 78.0 ± 27.2 75.6 ± 27.3 0.22
Fasting blood sugar(mg/dl) 105.8 ± 35.4 111.7 ± 40.0 0.03
ADMA (μmol/l) 0.46 ± 0.10 0.45 ± 0.10 0.66
L-arginine (μmol/l) 93.1 ± 30.9 94.4 ± 33.0 0.60
L-arginine/ADMA 210.3 ± 76.6 216.3 ± 82.9 0.30
Medications
Anti-platelet drug 269 (85.7) 423 (84.6) 0.68
Statins 129 (41.1) 216 (43.2) 0.55
ACE-Inhibitor/ARB 83 (26.4) 136 (27.2) 0.81
Calcium channel blocker 65 (20.7) 119(23.8) 0.30
Hypoglycemic treatments
Insulin (%) 19 (6.1) 40 (8.0) 0.30
OHA (%) 81 (25.8) 163 (32.6) 0.04
Insulin + OHA (%) 2 (0.6) 6 (1.2) 0.43
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. BMI:
body mass index; eGFR: estimated glomerular filtration rate; OHA: oral
hypoglycemic agents.
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detailed investigated in further studies.
Several studies have shown that elevated plasma
ADMA levels were present in patients with types 1 and
2 diabetes with retinopathy/nephropathy [10-12], and is
usually associated with a worse long-term cardiovascular
prognosis in diabetic patients [13,14]. However, in the
present study, the plasma ADMA level did not relate to
the risk of type 2 diabetes, but the L-arginine/ADMA
ratio did. This may be due to different ethnicity or clini-
cal characteristics of the study population, as our popu-
lation was composed of subjects referred for diagnostic
coronary angiography, and had a higher prevalence of
concomitant CAD and atherosclerosis risk factors such
as hypertension and hypercholesterolemia. In a large-
scale study of 3238 individuals scheduled for coronary
angiography, the plasma ADMA levels of patients with
type 2 diabetes were only marginally higher than those
of the patients without diabetes (0.83 μmol/l versus 0.82
μmol/l, p = 0.032) [35]. In another large community-
based population study, the mean plasma ADMA level
was similar between non-diabetic and diabetic subjects
(0.546 μmol/l versus 0.553 μmol/l, p = NS). Further-
more, in this study type 2 diabetes was a significant
independent predictor of plasma concentrations of
L-arginine and L-arginine/ADMA ratio, but not plasma
ADMA level [36], which is similar to our results. Inter-
estingly, Sibal et al. reported recently that the plasma
ADMA levels in patients with early type 1 diabetes with-
out macrovascular disease or macroalbuminuria were
even significantly lower compared to healthy controls.
In addition, the plasma ADMA levels were not asso-
ciated with impaired flow-mediated dilatation of brachial
arteries in these diabetic patients [37]. Therefore, these
conflicting evidences suggest that the association of
ADMA and type 2 diabetes is elusive. Since it has been
shown that increased NO synthase-derived free radical
production may be one of the resources of oxidative
stress in diabetes [38,39], one might speculate that the
inhibition of uncoupled endothelial NO synthase by
ADMA with resulting paradoxical reduction of oxidative
stress might be a possible explanation for the conflicting
relation of ADMA with cardiovascular events in patients
with uncomplicated diabetes [40]. In summary, these
findings suggest that the interactions among plasma
ADMA level, DDAH1 polymorphism, and type 2 dia-
betes are much more complex than previously thought
and are far from being completely understood. Thus,
Table 5 Association between the DDAH1 gene polymorphism and plasma ADMA levels, L-arginine levels and
L-arginine/ADMA ratio
SNP ID Genotype ADMA μmol/l mean (95% CI) L-arginine μmol/l mean (95% CI) L-arginine/ADMA mean (95% CI)
rs233112
AA 0.45 (0.43-0.46)* 95.8 (91.7-99.9) 222.5 (212.0-233.0)
AG 0.45 (0.44-0.46) 92.4 (89.2-95.5) 210.7 (202.9-218.5)
GG 0.47 (0.46-0.49) 95.1 (91.7-96.2) 209.3 (208.5-219.6)
rs1498374
GG 0.45 (0.44-0.46)* 93.8 (91.1-96.5) 216.2 (209.5-222.9)
GA 0.46 (0.45-0.47) 94.0 (89.8-98.2) 210.5 (200.0-220.9)
AA 0.51 (0.46-0.57) 94.7 (81.5-107.9) 214.0 (208.4-219.5)
rs1498373
CC 0.44 (0.43-0.45) *** 94.0 (90.6-97.3) 219.5 (211.0-227.9)
CT 0.46 (0.45-0.47) 93.3 (90.0-96.5) 210.4 (202.2-218.7)
TT 0.49 (0.46-0.52) 96.8 (89.2-104.5) 204.0 (187.7-219.6)
rs1241321
GG 0.45 (0.43-0.47) 94.8 (88.5-101.0) 220.1(203.5-236.6)
GA 0.45 (0.44-0.46) 94.2 (90.9-97.5) 215.1 (207.0-223.2)
AA 0.46 (0.45-0.47) 93.1 (89.7-96.6) 210.3 (201.8-218.8)
rs1403956
GG 0.45 (0.44-0.46)* 98.0 (91.1-96.9) 217.6 (210.2-224.9)
GA 0.46 (0.45-0.47) 93.2 (89.4-96.9) 209.4 (200.3-218.5 )
AA 0.49 (0.46-0.52) 98.7 (88.4-109.1) 203.3 (182.1-224.6)
rs587843
CC 0.46 (0.44-0.48) 92.3 (86.5-98.0) 207.7 (193.6-221.7)
CG 0.45 (0.44-0.46) 94.3 (91.2-97.2) 216.7 (209.3-224.3)
GG 0.46 (0.45-0.47) 94.2 (90.2-98.3) 212.8 (202.7-223.0)
*: p < 0.05, ***: p < 0.001, compared by one-way analysis of variance test.
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ADMA and type 2 diabetes are warranted.
There are several limitations in this study. First, our
study subjects were enrolled from individuals referred for
coronary angiography, and with higher prevalence of
CAD and risk factors of atherosclerosis. Confirmation in
a larger cohort of Chinese Han or a Caucasian population
and those with less co-morbidity may be mandatory.
Second, the information about complications of type 2
diabetes, including microalbuminemia, nephropathy and
retinopathy, was unavailable in this study. Considering
the close association of plasma ADMA with these dia-
betic complications in previous reports, studies investi-
gating their association with the DDAH1 polymorphisms
may be informative. Finally, it has been reported that sev-
eral pharmacological agents might lower the plasma
(A) All-cause mortality      (B) All-cause mortality 
(C)  MACE        (D)  MACE 
Figure 2 Kaplan-Meier survival analyses with all-cause mortality (A, B) and major adverse cardiovascular events (MACE) (C, D) during
follow-up according to the genotype of rs1241321 (AA___ vs. GG + AG....) in diabetic and non-diabetic groups. P values by log-rank
test were shown.
Table 6 Association of common haplotypes of DDAH1 gene and type 2 diabetes
Haplotype Allele Estimated frequency (%) OR (95% CI) P value
rs233112 rs1498374 rs1498373 rs1241321 rs1403956 rs587843
H1 A G C G G G 18.5 - -
H2 A G C A G G 16.0 0.76 (0.53-1.08) 0.13
H3 G A T A A G 15.2 0.95 (0.67-1.36) 0.79
H4 G G T G G C 13.7 1.18 (0.83-1.69) 0.36
H5 G G C A G C 13.2 0.67 (0.46-0.98) 0.04
H6 A G C A G C 9.8 0.97 (0.66-1.44) 0.89
H7 A G C A A G 6.7 0.88 (0.55-1.40) 0.58
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inhibitor/angiotensin receptor blocker and statins
[41,42], which were used more commonly in our diabetic
group. However, there were no significant differences in
plasma ADMA level between patients using angiotensin
converting enzyme inhibitor/angiotensin receptor
blocker (p = 0.59) and statins (p = 0.14) or not.
Conclusion
Our study provides the first evidence that SNP
rs1241321 in DDAH1 is associated with insulin sensitiv-
ity, type 2 diabetes and their long-term prognosis, inde-
pendently of plasma ADMA levels. The DDAH1 gene
may play a potential role in the pathogenesis of type
2 diabetes.
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